α-环己基苯乙酸 | 3894-09-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: α-环己基苯乙酸
• 中文别名: 环己基苯乙酸；2-环己基-2-苯乙酸；环已基苯乙酸
• 英文名称: 2-cyclohexyl-2-phenylacetic acid
• 英文别名: cyclohexylphenylacetic acid；α-cyclohexyl phenylacetic acid；α-phenylcyclohexaneacetic acid
• CAS: 3894-09-5
• 化学式: C₁₄H₁₈O₂
• 分子量: 218.296
• InChiKey: AAJLPPDFIRPBDA-UHFFFAOYSA-N

物化性质

• 熔点：
  148-152 °C
• 沸点：
  318.98°C (rough estimate)
• 密度：
  1.0317 (rough estimate)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、乙酸乙酯（少许）
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与碱、还原剂或氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2916399090
• 储存条件：
  密封储存，应存放在阴凉、干燥的库房中。

SDS

Name:	Cyclohexylphenylacetic Acid 99% Material Safety Data Sheet
Synonym:	None known
CAS:	3894-09-5

Section 1 - Chemical Product MSDS Name:Cyclohexylphenylacetic Acid 99% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3894-09-5	Cyclohexylphenylacetic Acid	99	223-443-3

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3894-09-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 151.50 - 153.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H18O2
Molecular Weight: 218.29

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3894-09-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Cyclohexylphenylacetic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 3894-09-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3894-09-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3894-09-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  α-环己基苯乙酸 在 platinum(IV) oxide 硫酸 、 氢气 、 硝酸 、 sodium nitrite 作用下， 10.0 ℃ 、98.06 kPa 条件下， 反应 14.25h， 生成 Cyclohexyl-(4-hydroxy-phenyl)-acetic acid methyl ester
  参考文献：
  名称：

  一系列新的环己基烷基胺衍生物的合成和心血管活性有关。

  摘要：

  已经合成了一系列与哌己啉相关的24种环己基烷基胺衍生物，并筛选了其心血管活性。所有化合物都含有被烷基，环烷基或芳烷基取代的环外胺。为了进一步降低毒性，进行了对甲苯基和对羟基苯基衍生物23和24的合成。已经系统地检查了相对于芳核分离环己胺部分的效果。根据以下标准顺序，进行药理学研究，以寻找活性优于哌克西林的化合物：（1）α-肾上腺素分解活性；（2）增加冠状动脉血流量；（3）钙拮抗作用。几种化合物比哌克西林更有效，毒性更低。

  DOI：

  10.1021/jm00348a019
• 作为产物：
  描述：

  2,2-二苯基乙酸 在 溶剂黄146 、 铂 作用下， 生成 α-环己基苯乙酸
  参考文献：
  名称：

  The Catalytic Hydrogenation of the Benzene Nucleus. VI. The Hydrogenation of Compounds with Two Benzene Rings

  摘要：

  DOI：

  10.1021/ja01179a056

文献信息

• Design, synthesis, and functional assessment of Cmpd-15 derivatives as negative allosteric modulators for the β2-adrenergic receptor
  作者：Kaicheng Meng、Paul Shim、Qingtin Wang、Shuai Zhao、Ting Gu、Alem W. Kahsai、Seungkirl Ahn、Xin Chen

  DOI：10.1016/j.bmc.2018.03.023

  日期：2018.5

  The β2-adrenergic receptor (β2AR), a G protein-coupled receptor, is an important therapeutic target. We recently described Cmpd-15, the first small molecule negative allosteric modulator (NAM) for the β2AR. Herein we report in details the design, synthesis and structure-activity relationships (SAR) of seven Cmpd-15 derivatives. Furthermore, we provide in a dose-response paradigm, the details of the

  所述β 2 -肾上腺素能受体（β 2 AR），G蛋白偶联受体，是一个重要的治疗目标。我们最近描述CMPD-15，第一小分子负变构调节剂（NAM）为β 2 AR。本文中，我们详细报告了7种Cmpd-15衍生物的设计，合成和构效关系（SAR）。此外，我们提供一种在剂量-响应范例，它们的衍生物的效果的细节在调节激动剂诱导的β 2在放射性配体竞争结合试验中，AR活性（G蛋白介导的cAMP产生和β-arrestin募集到受体）以及正构激动剂的结合亲和力。我们的研究结果表明，一些修改，包括在除去甲酰胺基的第-formamido苯丙氨酸区域和溴在元-bromobenzyl甲基苯甲酰胺区域引起CMPD-15的功能活性显着降低。这些SAR结果提供了宝贵的见解NAM CMPD-15的作用机制以及为更有效和选择性调节剂的未来发展，为β的基础2基于CMPD-15的化学支架AR。
• Clicked AC regioisomer cationic cyclodextrins for enantioseparation
  作者：Jie Zhou、Yun Liu、Yingying Lu、Jian Tang、Weihua Tang

  DOI：10.1039/c4ra06279e

  日期：——

  Novel AC regioisomer cationic cyclodextrins have been successfully prepared with azide/alkyne click chemistry. The clicked CDs were explored for the enantioseparation of acidic racemates in capillary electrophoresis.

  通过叠氮/炔点击化学，成功制备了一系列新型AC区域异构阳离子环糊精。这些点击合成的环糊精被探索用于毛细管电泳中酸性消旋体的对映体拆分。
• [EN] 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS<br/>[FR] DERIVES DE L'ACIDE 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIQUE EN TANT QU'ANTAGONISTES DE CRTH2
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2006021418A1

  公开（公告）日：2006-03-02

  The invention relates to 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives and their use as potent 'chemoattractant receptor-homologous molecule expressed on Th2 cells' antagonists in the treatment of prostaglandin mediated diseases, to pharmaceutical compositions containing these derivatives and to processes for their preparation.

  这项发明涉及2-硫代基苯并咪唑-1-基乙酸衍生物及其在治疗前列腺素介导的疾病中作为强效“趋化受体同源分子在Th2细胞上表达”的拮抗剂的用途，涉及含有这些衍生物的药物组合物以及其制备方法。
• NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS
  申请人：Stewart Andrew O.

  公开号：US20100130558A1

  公开（公告）日：2010-05-27

  The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L 1 , L 2 , R 1 , R 2 , and R 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式（I）化合物的钙通道抑制剂，其中L1、L2、R1、R2和R3如规范中所定义。本申请还涉及包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：SPINIFEX PHARM PTY LTD

  公开号：WO2013102242A1

  公开（公告）日：2013-07-11

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及用于拮抗血管紧张素II型2（AT2）受体的杂环化合物。更具体地，本发明涉及吡咯烷和氮杂环丙烷化合物，含有它们的组合物以及它们在治疗或预防与AT2受体功能相关的疾病或疾病的方法中的使用，包括神经病性疼痛、炎症性疼痛、与神经元过敏、神经传导速度受损、细胞增殖紊乱、骨吸收和骨形成之间失衡以及与异常神经再生相关的疾病。

表征谱图